Advanced Solid Tumors Clinical Trial
Official title:
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of RO7589831 in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR)
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of RO7589831 monotherapy in participants with microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) advanced solid tumors. RO7589831 is an oral drug that acts on a protein called Werner (WRN), which may promote the growth of cancers that are MSI and/or dMMR. By acting on WRN, RO7589831 may be able to block the growth of these types of cancer.
Status | Recruiting |
Enrollment | 220 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 22, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 - Have a locally confirmed microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor - Have received and then progressed following or are intolerant to at least 1 standard treatment regimen in the advanced setting - Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 - Life expectancy of at least (=)12 weeks - Availability of formaldehyde-fixed paraffin-embedded (FFPE) archival tumor tissue for submission to Sponsor/central laboratory for retrospective central testing; for participants without archival tissue, a biopsy from either primary or metastatic tumor lesion, deemed medically feasible, must be taken - Adequate hematologic, end-organ, and cardiovascular function, as defined in the protocol Exclusion Criteria: - Inability or unwillingness to swallow pills - Malabsorption syndrome or other condition that would interfere with enteral absorption - Known hypersensitivity or intolerance to ingredients from the study drug formulation including patients with rare genetic disorders such as galactosaemia, glucose-galactose intolerance or congenital lactase deficiency - Known uncontrolled central nervous system (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control) and/or carcinomatous meningitis - Known active or uncontrolled bacterial, viral, fungal, mycobacterial (including but not limited to tuberculosis and atypical mycobacterial disease), parasitic, or other infection (excluding fungal infections of nail beds), or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 2 weeks prior to the start of drug administration (related to the completion of the course of antibiotics, except if for tumor fever) or 6 months for any intracranial abscess - Has a positive test at screening for hepatitis B virus, hepatitis C virus, or for human immodeficiency virus (HIV), per local diagnostic standard and in accordance with local laws and regulations - Uncontrolled diabetes or symptomatic hyperglycemia (i.e., well controlled defined as a screening hemoglobin A1c <8% and no urinary ketoacidosis) - Alcohol or drug dependence or abuse - Patients with known Werner (WRN) syndrome - Prior treatment with any WRN helicase inhibitor - Pregnancy, breastfeeding, or intention of becoming pregnant during the study |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Leuven Gasthuisberg | Leuven | |
Canada | Princess Margaret Cancer Center | Toronto | Ontario |
Canada | BCCA-Vancouver Cancer Centre | Vancouver | British Columbia |
Denmark | Rigshospitalet; Onkologisk Klinik | København Ø | |
France | CLCC Leon Berard Lyon | Lyon | |
France | Gustave Roussy | Villejuif | |
Spain | Vall d?Hebron Institute of Oncology (VHIO), Barcelona | Barcelona | |
Spain | Clinica Universidad de Navarra Madrid; Servicio de Oncología | Madrid | |
Spain | START Madrid. Centro Integral Oncologico Clara Campal; CIOCC | Madrid | |
Spain | Clinica Universitaria de Navarra; Servicio de Oncologia | Pamplona | Navarra |
Spain | Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia | Valencia | |
United Kingdom | Royal Marsden Hospital - Fulham | London | |
United Kingdom | Sarah Cannon Research Institute | London | |
United Kingdom | The Christie | Manchester | |
United States | City of Hope | Duarte | California |
United States | Duke University; Office of Research Contracts | Durham | North Carolina |
United States | MD Anderson Cancer Center | Houston | Texas |
United States | City of Hope at Irvine Lennar | Irvine | California |
United States | SCRI Oncology Partners | Nashville | Tennessee |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
United States, Belgium, Canada, Denmark, France, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Adverse Events, with Severity Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI CTCAE v5.0) | From first dose of study drug until 30 days after last dose of study drug (up to approximately 15 months) | ||
Primary | Incidence of Dose-Limiting Toxicities | Cycle 1 (1 cycle is 3 weeks) | ||
Secondary | Maximum Plasma Concentration Observed (Cmax) of RO7589831 | At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months) | ||
Secondary | Time of Maximum Plasma Concentration Observed (Tmax) of RO7589831 | At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months) | ||
Secondary | Area Under the Plasma Concentration-Time Curve (AUC) of RO7589831 | At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months) | ||
Secondary | Apparent Oral Clearance (CL/F) of RO7589831 | At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months) | ||
Secondary | Volume of Distribution (V/F) of RO7589831 | At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months) | ||
Secondary | Terminal Half-Life (T1/2) of RO7589831 | At prespecified timepoints in Cycles 1, 2, and 3, and every 2 cycles thereafter (1 cycle is 3 weeks) until last dose of study drug (up to approximately 15 months) | ||
Secondary | Objective Response Rate | From start of study treatment until end of follow-up (up to approximately 36 months) | ||
Secondary | Disease Control Rate | From start of study treatment until end of follow-up (up to approximately 36 months) | ||
Secondary | Duration of Response | From the time of first occurrence of a documented response until the time of documented disease progression or death from any cause, whichever occurs first (up to approximately 36 months) | ||
Secondary | Progression-Free Survival, as Assessed by the Investigator | From start of study treatment to the first occurrence of documented disease progression or death from any cause, whichever occurs first (up to approximately 36 months) | ||
Secondary | Overall Survival | From start of study treatment to the time of death from any cause (up to approximately 36 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04972981 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT05086822 -
A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03260322 -
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT06040541 -
Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05862831 -
Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03641794 -
Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT03665129 -
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05914116 -
A Study of DB-1311 in Advanced/Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01693562 -
A Phase 1/2 Study to Evaluate MEDI4736
|
Phase 1/Phase 2 | |
Recruiting |
NCT04387916 -
A Study of KC1036 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04095273 -
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
|
Phase 1 | |
Not yet recruiting |
NCT03692520 -
Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT02997176 -
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
|
Phase 1 | |
Recruiting |
NCT04446260 -
A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02253992 -
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06076291 -
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03545971 -
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
|
Phase 1 |